Rodman & Renshaw Starts Oasmia Pharmaceuticals (OASM) at Buy

September 12, 2016 7:27 AM EDT
Get Alerts OASM Hot Sheet
Price: $2.70 +4.25%

Rating Summary:
    1 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade OASM Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Rodman & Renshaw initiated coverage on Oasmia Pharmaceuticals (NASDAQ: OASM) with a Buy rating and a price target of $6. Analyst Raghuram Selvaraju highlighted its risk-mitigated, cost-effective approach to drug development.

"In our view, this company constitutes a risk-mitigated opportunity due to: (1) its exclusive focus on developing next-generation formulations of approved drugs with well-known efficacy profiles in oncology indications; (2) its strategy to secure product approvals based on the 505(b)(2) regulatory pathway in the U.S. and the Mixed Application pathway in Europe, which permits accelerated review and allows submission of data facilitating approval based on clinical bioequivalence against marketed agents rather than head-to-head efficacy trials; (3) Oasmia's targeting of both human and veterinary health applications; and (4) its unique ability to develop truly water-soluble formulations, which eschew a need for toxic excipients and thus provide the advantage of better safety and tolerability while improving dosing simplicity and convenience," said Selvaraju.

For an analyst ratings summary and ratings history on Oasmia Pharmaceuticals click here. For more ratings news on Oasmia Pharmaceuticals click here.

Shares of Oasmia Pharmaceuticals closed at $3.40 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Rodman & Renshaw

Add Your Comment